Sphere Fluidics has announced the launch of Cyto-Mine Chroma, its next generation single-cell analysis platform alongside the opening of its Early Access Program.
Unveiled at SLAS2025 International Conference and Exhibition – the annual event of the Society for Laboratory Automation and Screening – taking place in San Diego, Cyto-Mine Chroma represents the next generation of Sphere Fluidics’ industry-leading Cyto-Mine single-cell analysis platform. The Early Access Program provides an opportunity to be among the first to demo the Cyto-Mine Chroma for faster project timeline completion and improved outcomes across broad applications, including antibody discovery, cell line development, and emerging areas such as cell therapy. Through the project, Sphere Fluidics will collaborate closely with forward-thinking customers to drive innovation and inform the development of future applications and assays on the platform.
Offering enhanced capabilities, including multiplexing and greater assay flexibility, Cyto-Mine Chroma has been developed to maximise the efficiency and precision of single-cell functional analysis – enabling tens of millions of cells to be screened in a day. Leveraging a four-colour laser and detector system, Cyto-Mine Chroma expands the number of parameters that can be analysed for each cell in a single assay. This supports the upcoming launch of the firm’s first multiplexed assay kit, facilitating multiple readouts within a single experiment, optimising the throughput and precision of cell selection. By accelerating the early selection of superior candidate cells for downstream expansion or further analysis, overall timelines are reduced from months to weeks, while reducing effort and cost.
“The next-generation Cyto-Mine Chroma platform has been designed to transform single-cell analysis,” commented Dale Levitzke, CEO, Sphere Fluidics. “We are excited to unveil this innovative platform and its Early Access Program at SLAS, the premier event for laboratory automation and screening. This launch underscores our dedication to advancing biotechnology. Collaborating closely with key industry stakeholders and researchers will allow us to ensure our microfluidic technologies meet the evolving needs of the sector, both now and in the future.”
To learn more about Cyto-Mine Chroma, please visit https://spherefluidics.com/our-products/platform-products/cyto-mine-chroma/